Clinical Trials Browser

Recruiting × Interventional × Adenoma, Islet Cell × Clear all

NCT05687123 2026-04-21

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Phase 1 Recruiting

24 enrolled

Gastrointestinal

Adenoma, Islet Cell, Pancreatic Neoplasms

NCT06881992 2026-04-17

Tumor HI

Phase 3 Recruiting

16 enrolled

EndocrineNETSarcoma

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Phase 2/3 Recruiting

440 enrolled

EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT04924075 2026-04-13

MK-6482-015

Phase 2 Recruiting

322 enrolled 2 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07165132 2026-04-13

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 Recruiting

104 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT06141369 2026-04-09

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Phase NA Recruiting

21 enrolled

Endocrine

Adenoma, Islet Cell, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04119024 2026-03-17

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Phase 1 Recruiting

18 enrolled

BreastCNSDermatologicEndocrineHead & NeckNETThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Uveal Melanoma, Breast Neoplasms, Adenoma, Islet Cell, Melanoma, Neoplasm Metastasis, Paraganglioma, Pheochromocytoma, Thyroid Neoplasms, Adrenocortical Carcinoma, Neuroendocrine Tumors

NCT06202066 2026-03-11